Focus Partners Wealth
NKTR icon

Focus Partners Wealth’s Nektar Therapeutics NKTR Stock Holding History

Focus Partners Wealth’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$895K Buy
+12,826
New +$939K ﹤0.01% 1689
2025
Q2 		– Sell
-861
Closed -$8.79K – 2101
2025
Q1 		$8.79K Buy
+861
New +$11.3K ﹤0.01% 1888

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Focus Partners Wealth's NKTR Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 12,826 shares worth $895K. The stake represents ﹤0.01% of the portfolio and ranks #1689 among its holdings. This is a return to the name: Focus Partners Wealth previously reported a position in NKTR as recently as Q1 2025.

Focus Partners Wealth first reported a position in NKTR in Q1 2025 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Focus Partners Wealth held 12,826 shares of Nektar Therapeutics worth $895K as of Q2 2026.
  • Nektar Therapeutics was a new Focus Partners Wealth position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1689 holding.
  • Focus Partners Wealth first reported a position in Nektar Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.